Importer of Controlled Substances; Notice of Registration, 44284-44285 [2010-18486]
Download as PDF
<![CDATA[
44284
Federal Register / Vol. 75, No. 144 / Wednesday, July 28, 2010 / Notices
to pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. Imperial Oil Co., et al., Civil
Action No. 07cv1486 (D.N.J.), D.J. Ref.
90–11–2–946/1.
The Decree may be examined at U.S.
EPA Region II, U.S. Environmental
Protection Agency, 290 Broadway, New
York, New York 10007. During the
public comment period, the Decree may
also be examined on the following
Department of Justice Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Decree may also be obtained by mail
from the Consent Decree Library, P.O.
Box 7611, U.S. Department of Justice,
Washington, DC 20044–7611 or by
faxing or e-mailing a request to Tonia
Fleetwood (tonia.fleetwood@usdoj.gov),
fax no. (202) 514–0097, phone
confirmation number (202) 514–1547. In
requesting a copy from the Consent
Decree Library, please enclose a check
in the amount of $15.25 (25 cents per
page reproduction cost) payable to the
U.S. Treasury or, if by e-mail or fax,
forward a check in that amount to the
Consent Decree Library at the stated
address.
Maureen Katz,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 2010–18439 Filed 7–27–10; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
sroberts on DSKD5P82C1PROD with NOTICES
Notice of Lodging of Consent Decree
Pursuant to the Comprehensive
Environmental Response,
Compensation, and Liability Act
Notice is hereby given that on July 15,
2010, a proposed consent decree in
United States, et al. v. PPL Electric
Utilities Corporation, et al., Civil Action
No. 10-cv-3477, was lodged with the
United States District Court for the
Eastern District of Pennsylvania.
The proposed consent decree resolves
claims that the United States filed under
Sections 106 and 107(a) of CERCLA, 42
U.S.C. 9606 and 9607(a), for
performance of work and
reimbursement of costs incurred and to
be incurred in connection with response
actions at the UGI Columbia Gas Plant
Superfund Site (‘‘Site’’) in Columbia
Borough, Lancaster County,
Pennsylvania. Under the proposed
consent decree, the Settling Defendants,
PPL Electric Utilities Corporation and
UGI Utilities Inc., will reimburse the
United States $606,114.53 for past
VerDate Mar<15>2010
19:05 Jul 27, 2010
Jkt 220001
response costs, will pay future response
costs to be incurred by the United
States, and will perform long-term
monitoring, operation, and maintenance
of the remedy for the Site. The proposed
consent decree also resolves the
Commonwealth of Pennsylvania’s
claims for past response costs under the
Pennsylvania Hazardous Sites Cleanup
Act (‘‘HSCA’’), 35 P.S. § 6020.101, et eq.,
for an amount of $17,430.94.
The Department of Justice will
receive, for a period of thirty (30) days
from the date of this publication
comments relating to the proposed
consent decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and either e-mailed
to pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC,
20044–7611, and should refer to United
States, et al. v. PPL Electric Utilities
Corporation, et al., DOJ No. 90–11–3–
09216.
The proposed consent decree may be
examined at the office of the United
States Attorney’s Office, 615 Chestnut
Street, Suite 1250, Philadelphia, PA
19106 and at U.S. EPA Region III, 1650
Arch Street, Philadelphia, PA 19103.
During the public comment period, the
proposed consent decree may also be
examined on the following Department
of Justice Web site, https://
www.usdoj.gov/endr/
Consent_Decrees.html. A copy of the
proposed consent decree may be
obtained in person or by mail from the
Consent Decree Library, P.O. Box 7611,
U.S. Department of Justice, Washington,
DC 20044–7611 or by faxing or
e-mailing a request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy from the Consent Decree Library,
please enclose a check in the amount of
$___, (25 cents per page reproduction
cost) payable to the U.S. Treasury or, if
by e-mail or fax, forward a check in that
amount to the Consent Decree Library at
the stated address.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment & Natural
Resources Division.
[FR Doc. 2010–18440 Filed 7–27–10; 8:45 am]
BILLING CODE 4410–15–P
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (NIJ) Docket No. 1525]
Notice of Draft NIJ Criminal Justice
Restraints Selection and Application
Guide
National Institute of Justice,
Office of Justice Programs, Department
of Justice.
AGENCY:
Notice of Draft NIJ Criminal
Justice Restraints Selection and
Application Guide.
ACTION:
In an effort to obtain
comments from interested parties, the
U.S. Department of Justice, Office of
Justice Programs, National Institute of
Justice (NIJ) will make available to the
general public the draft ‘‘NIJ Criminal
Justice Restraints Selection and
Application Guide.’’ The opportunity to
provide comments on this document is
open to industry technical
representatives, criminal justice
agencies and organizations, research,
development and scientific
communities, and all other stakeholders
and interested parties. Those
individuals wishing to obtain and
provide comments on the draft
documents under consideration are
directed to the following Web site:
https://www.justnet.org.
SUMMARY:
Comments must be received on
or before August 27, 2010.
DATES:
FOR FURTHER INFORMATION CONTACT:
Casandra Robinson, by telephone at
202–305–2596 [Note: this is not a tollfree telephone number], or by e-mail at
casandra.robinson@usdoj.gov.
Kristina Rose,
Acting Director, National Institute of Justice.
[FR Doc. 2010–18468 Filed 7–27–10; 8:45 am]
BILLING CODE 4410–18–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated April 20, 2010, and
published in the Federal Register on
April 26, 2010, (75 FR 21660), Mylan
Pharmaceuticals Inc., 781 Chestnut
Ridge Road, Morgantown, West Virginia
26505, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
E:\FR\FM\28JYN1.SGM
28JYN1
44285
Federal Register / Vol. 75, No. 144 / Wednesday, July 28, 2010 / Notices
Drug
Schedule
Methylphenidate (1724) ................
Fentanyl (9801) ............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated April 20, 2010, and
published in the Federal Register on
April 26, 2010, (75 FR 21661), Almac
Clinical Services Inc., (ACSI), 2661
Audubon Road, Audubon, Pennsylvania
19403, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
The company plans to import the
listed controlled substances to
manufacture bulk controlled substance
intermediates for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Penick Corporation to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Penick
Corporation to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–18475 Filed 7–27–10; 8:45 am]
[FR Doc. 2010–18476 Filed 7–27–10; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
By Notice dated April 26, 2010 and
published in the Federal Register on
April 30, 2010, (75 FR 22844), Penick
Corporation, 33 Industrial Park Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Schedule
Coca Leaves (9040) .....................
Opium, raw (9600) .......................
Poppy Straw (9650) .....................
Concentrate of Poppy Straw
(9670).
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances: Notice of Application
Importer of Controlled Substances:
Notice of Registration
DEPARTMENT OF JUSTICE
sroberts on DSKD5P82C1PROD with NOTICES
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Almac Clinical Services Inc. (ACSI) to
import the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Almac Clinical Services
Inc. (ACSI) to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Drug Enforcement Administration
BILLING CODE 4410–09–P
Jkt 220001
II
II
II
DEPARTMENT OF JUSTICE
[FR Doc. 2010–18486 Filed 7–27–10; 8:45 am]
19:05 Jul 27, 2010
Schedule
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Fentanyl (9801) ............................
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Mylan Pharmaceuticals Inc., to import
the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Mylan Pharmaceuticals
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
VerDate Mar<15>2010
Drug
II
II
II
II
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 27, 2009,
Johnson Matthey Pharmaceutical
Materials, Inc., Pharmaceuticals Service,
25 Patton Road, Devens, Massachusetts
01434, made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Nabilone (7379) ............................
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Remifentanil (9739) ......................
Hydrocodone (9193) .....................
Schedule
II
II
II
II
II
II
II
The company plans to utilize this
facility to manufacture small quantities
E:\FR\FM\28JYN1.SGM
28JYN1
]]>Agencies
[Federal Register Volume 75, Number 144 (Wednesday, July 28, 2010)]
[Notices]
[Pages 44284-44285]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-18486]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated April 20, 2010, and published in the Federal
Register on April 26, 2010, (75 FR 21660), Mylan Pharmaceuticals Inc.,
781 Chestnut Ridge Road, Morgantown, West Virginia 26505, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as an importer of the basic classes of controlled
substances listed in schedule II:
[[Page 44285]]
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methylphenidate (1724)..................... II
Fentanyl (9801)............................ II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
finished dosage form (FDF) from foreign sources for analytical testing
and clinical trials in which the foreign FDF will be compared to the
company's own domestically-manufactured FDF. This analysis is required
to allow the company to export domestically-manufactured FDF to foreign
markets.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the
registration of Mylan Pharmaceuticals Inc., to import the basic classes
of controlled substances is consistent with the public interest, and
with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971, at this time. DEA
has investigated Mylan Pharmaceuticals Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic classes of controlled
substances listed.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-18486 Filed 7-27-10; 8:45 am]
BILLING CODE 4410-09-P
